Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27244222 | 0.88 | PARP10 (0.49) | MAPTLMNAPOLBNPSR1ALDH1A1 | |
| SCHEMBL27243795 | 0.86 | MAPT (0.51) | MAPTLMNAPOLBGAAALDH1A1 | |
| SCHEMBL22249309 | 0.80 | KDM4E (0.36) | MAPTLMNAPOLBALDH1A1HPGD | |
| SCHEMBL22233284 | 0.80 | ALDH1A1 (0.43) | MAPTLMNAPOLBGAAALDH1A1 | |
| SCHEMBL6507499 | 0.79 | LMNA (0.49) | LMNAALDH1A1MAOA | |
| SCHEMBL1931571 | 0.79 | ALDH1A3 (0.42) | MAPTLMNAL3MBTL1ALDH1A1HPGD | |
| SCHEMBL22233863 | 0.79 | CA2 (0.39) | MAPTLMNAPOLBALDH1A1HPGD | |
| SCHEMBL3603475 | 0.79 | ALDH1A3 (0.42) | MAPTLMNAL3MBTL1ALDH1A1HPGD | |
| SCHEMBL11699645 | 0.77 | MAPT (0.58) | MAPTLMNAPOLBNPSR1L3MBTL1 | |
| SCHEMBL8719655 | 0.77 | MMP12 (0.43) | MAPTLMNAALDH1A1MAOBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | MAPT 3714/4885LMNA 407/4885POLB 2426/4885 |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | MAPT 3714/4885LMNA 407/4885POLB 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.